IP Library Granted Patent US 8,673,891
Granted Patent B2
US 8,673,891 · App. 13/147,001 · Granted Mar 18, 2014

Aminopyrazine derivative and medicine

Inventors: Hidetaka Fujihara (Kyoto, JP); Tetsuo Asaki (Uji, JP); Katsutoshi Hori (Kusatsu, JP); Haruna Naito (Kyoto, JP)
Assignee: Nippon Shinyaku Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,673,891
App. No.
13/147,001
Granted
Mar 18, 2014
Kind
B2
Abstract

The present invention relates to a compound represented by general formula [1] satisfying the following (I) or (II), or a pharmaceutical acceptable salt of the compound. (I) X is CH or N; R 1 is a halogen atom, and R 2 is H, a halogen atom, CN, [2], [3], [8], [9], an —O-alkyl, an —O-(saturated ring), etc. [2]: —C(R C )(R D )(R E ) (R C to R E each are H, an alkyl, etc.) [3]: —N(R F )(R G ) (R F and R G each are H, OH, amino, a (hetero)aryl, etc.) [8]: —C(═O)R L (R L is an alkyl, OH, an alkoxy, amino, etc.) [9]: a (substituted)phenyl; (II) X is >C—C(—O)R B (R B is a (substituted)amino, an alkoxy, OH, etc.); R 1 is a halogen atom; R 2 is H; R 3 is H or OH; and R 3 and R 4 each are H or an alkyl.

Claims (544)

1. A compound represented by the following general formula [1] or a pharmaceutically acceptable salt thereof,

wherein the compound is defined by the following (I) or (II)

(I):

X represents CH or N;

R 1 represents halogen;

R 2 represents:

(1) H,

(2) halogen,

(3) cyano,

(4) a group represented by the following general formula [2]:

(wherein * indicates the binding position; and R C , R D and R E are the same or different and each represents (a) H, or (b) alkyl optionally substituted by hydroxy or alkoxy, or alternatively two of R C , R D and R E are taken together with the adjacent C to represent a N-contaning saturated heterocyclic group, and the other one is H, the saturated heterocyclic group optionally substituted by alkylsulfonyl),

(5) a group represented by the following general formula [3]:

(wherein * has the same meaning as described above; and R F and R G are the same or different and each represents (a) H, (b) alkyl optionally substituted by one or two groups selected from the group consisting of hydroxy, amino, dialkylamino, a saturated cyclic amino group, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl optionally substituted by alkyl, tetrahydrofuranyl, and carbamoyl, (c) alkylcarbonyl, (d) alkylsulfonyl, (e) carbamoyl, or (f) heteroaryl optionally substituted by alkyl, or alternatively R F and R G are taken together with the adjacent N to represent a saturated cyclic amino group, which may optionally be substituted by one or two groups selected from the group consisting of (a) halogen, (b) cyano, (c) hydroxy, (d) alkyl optionally substituted by one or two groups selected from the group consisting of hydroxy, alkoxy, amino, alkoxycarbonylamino, alkylsulfonylamino, and alkylcarbonylamino, (e) cycloalkyl, (f) haloalkyl, (g) alkoxy, (h) oxo, (i) a group represented by the following general formula [4]:

(wherein * has the same meaning as described above; and R H represents alkyl or aryl), (j) a group represented by the following general formula [5]:

(wherein * has the same meaning as described above; and R I and R J are the same or different and each represents H, alkyl, carbamoyl, alkylcarbonyl, or alkylsulfonyl), (k) a group represented by the following general formula [6]:

(wherein * has the same meaning as described above; and R K represents alkyl, hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, (cycloalkyl)alkylamino, (hydroxyalkyl)amino, (alkoxyalkyl)amino, alkoxy, alkylsulfonylamino, or a saturated cyclic amino group), and (l) a saturated cyclic amino group optionally substituted by hydroxyl; and the staturated cyclic amino group, which is formed by combining R F , R G and the adjacent N, may form a spiro-linkage with a group represented by the following general formula [7A] or [7B]:

(wherein * has the same meaning as described above)),

(6) a group represented by the following general formula [8]:

(wherein * has the same meaning as described above; and R L represents (a) alkyl, (b) hydroxy, (c) alkoxy, (d) a saturated cyclic amino group optionally substituted by alkyl or alkylsulfonyl, or (e) an amino optionally substituted by one or two groups selected from the group consisting of alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, haloalkyl, dialkylaminoalkyl, alkoxyalkyl, and hydroxyalkyl),

(7) a group represented by the following general formula [9]:

(wherein * has the same meaning as described above; and R M , R N and R O are the same or different and each represents H, halogen, cyano, alkoxy, carbamoyl, sulfamoyl, monoalkylaminosulfonyl, or alkylsulfonyl, or alternatively two of R M , R N and R O are taken together to represent methylenedioxy),

(8) —OR P (R P represents an alkyl optionally substituted by a group selected from the group consisting of hydroxy, dialkylamino, alkoxy, tetrahydrofuranyl, and cycloalkyl, or an optionally O-containing saturated cyclic group optionally substituted by hydroxy), or

(9) a heteroaryl optionally substituted by one or two groups selected from the group consisting of cyano, halogen, hydroxy, alkoxy, alkylcarbonyl, carbamoyl, alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, hydroxycarbonyl and alkoxyalkyl;

R 3 represents H or hydroxy;

R 4 represents H or alkyl; and

R 5 represents H or alkyl;

(II):

X represents —CR A ;

R A represents a group represented by the following general formula [10]:

(wherein * has the same meaning as described above; and R B represents (a) amino optionally substituted by one or two groups selected from the group consisting of alkyl, cycloalkyl, (cycloalkyl)alkyl, and alkoxyalkyl, (b) alkoxy, (c) hydroxy, or (d) a saturated cyclic amino group);

R 1 represents halogen;

R 2 represents H;

R 3 represents H or hydroxy;

R 4 represents H or alkyl; and

R 5 represents H or alkyl.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1 ,

wherein the compound represented by the general formula [1] is defined by the following [i] or [ii]:

[i]:

X is CH or N;

R 1 is halogen;

R 2 is:

(1) a group represented by the following general formula [11]:

(wherein * indicates the binding position; and R F1 and R G1 are the same or different and each represents (a) H, (b) an alkyl optionally substituted by one or two groups selected from the group consisting of hydroxy, amino, dialkylamino, a saturated cyclic amino group, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl optionally substituted by alkyl, tetrahydrofuranyl, and carbamoyl, (c) alkylcarbonyl, (d) alkylsulfonyl, (e) carbamoyl, or (f) heteroaryl optionally substituted by alkyl, or alternatively, R F1 and R G1 are taken together with the adjacent N to represent a saturated cyclic amino group, which may optionally be substituted by one or two groups selected from the group consisting of (a) halogen, (b) cyano, (c) hydroxy, (d) alkyl optionally substituted by one or two groups selected from the group consisting of hydroxy, alkoxy, amino, alkoxycarbonylamino, alkylsulfonylamino and alkylcarbonylamino, (e) cycloalkyl, (f) haloalkyl, (g) alkoxy, (h) oxo, (i) a group represented by the following general formula [4]:

(wherein * has the same meaning as described above; and R H represents alkyl or aryl), (j) a group represented by the following general formula [5]:

(wherein * has the same meaning as described above; and R I and R J are the same or different and each represents H, alkyl, carbamoyl, alkylcarbonyl, or alkylsulfonyl), (k) a group represented by the following general formula [6]:

(wherein * has the same meaning as described above; and R K represents alkyl, hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, (cycloalkyl)alkylamino, (hydroxyalkyl)amino, (alkoxyalkyl)amino, alkoxy, alkylsulfonylamino, or a saturated cyclic amino group), and (l) a saturated cyclic amino group optionally substituted by hydroxyl,

(2) a group represented by the following general formula [8]:

(wherein * has the same meaning as described above; and R L represents (a) alkyl, (b) hydroxy, (c) alkoxy, (d) a saturated cyclic amino group optionally substituted by alkyl or alkylsulfonyl, or (e) an amino optionally substituted by one or two groups selected from the group consisting of alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, haloalkyl, dialkylaminoalkyl, alkoxyalkyl, and hydroxyalkyl),

(3) a group represented by the following general formula [9]:

(wherein * has the same meaning as described above; and R M , R N and R O are the same or different and each represents H, halogen, cyano, alkoxy, carbamoyl, sulfamoyl, monoalkylaminosulfonyl, or alkylsulfonyl, or alternatively two of R M , R N and R O are taken together to represent methylenedioxy),

(4) —OR P1 (wherein R P1 represents an alkyl optionally substituted by a group selected from the group consisting of hydroxy, dialkylamino, alkoxy, tetrahydrofuranyl, and cycloalkyl), or

(5) a heteroaryl optionally substituted by one or two groups selected from the group consisting of cyano, halogen, hydroxy, alkoxy, alkylcarbonyl, carbamoyl, alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, hydroxycarbonyl and alkoxyalkyl;

R 3 is H or hydroxy;

R 4 is H or alkyl; and

R 5 is H or alkyl;

[ii]:

X is —CR A ;

R A is a group represented by the following general formula [10]:

(wherein * has the same meaning as described above; and R B represents (a) amino optionally substituted by one or two groups selected from the group consisting of alkyl, cycloalkyl, (cycloalkyl)alkyl, and alkoxyalkyl, (b) alkoxy, (c) hydroxy, or (d) a saturated cyclic amino group);

R 1 is halogen;

R 2 is H;

R 3 is H or hydroxy;

R 4 is H or alkyl; and

R 5 is H or alkyl.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1 ,

wherein:

X is CH;

R 1 is halogen;

R 2 is:

(1) a group represented by the following general formula [11]:

(wherein * indicates the binding position; and R F1 and R G1 are the same or different and each represents (a) H, (b) an alkyl optionally substituted by one or two groups selected from the group consisting of hydroxy, amino, dialkylamino, a saturated cyclic amino group, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl optionally substituted by alkyl, tetrahydrofuranyl, and carbamoyl, (c) alkylcarbonyl, (d) alkylsulfonyl, (e) carbamoyl, or (f) heteroaryl optionally substituted by alkyl, or alternatively, R F1 and R G1 are taken together with the adjacent N to represent a saturated cyclic amino group, which may optionally be substituted by one or two groups selected from the group consisting of (a) halogen, (b) cyano, (c) hydroxy, (d) alkyl optionally substituted by one or two groups selected from the group consisting of hydroxy, alkoxy, amino, alkoxycarbonylamino, alkylsulfonylamino and alkylcarbonylamino, (e) cycloalkyl, (f) haloalkyl, (g) alkoxy, (h) oxo, (i) a group represented by the following general formula [4]:

(wherein * has the same meaning as described above; and R H represents alkyl or aryl), (j) a group represented by the following general formula [5]:

(wherein * has the same meaning as described above; and R I and R J are the same or different and each represents H, alkyl, carbamoyl, alkylcarbonyl, or alkylsulfonyl), (k) a group represented by the following general formula [6]:

(wherein * has the same meaning as described above; and R K represents alkyl, hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, (cycloalkyl)alkylamino, (hydroxyalkyl)amino, (alkoxyalkyl)amino, alkoxy, alkylsulfonylamino, or a saturated cyclic amino group), and (l) a saturated cyclic amino group optionally substituted by hydroxyl,

(2) a group represented by the following general formula [8]:

(wherein * has the same meaning as described above; and R L represents (a) alkyl, (b) hydroxy, (c) alkoxy, (d) a saturated cyclic amino group optionally substituted by alkyl or alkylsulfonyl, or (e) an amino optionally substituted by one or two groups selected from the group consisting of alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, haloalkyl, dialkylaminoalkyl, alkoxyalkyl, and hydroxyalkyl),

(3) a group represented by the following general formula [9]:

(wherein * has the same meaning as described above; and R M , R N and R O are the same or different and each represents H, halogen, cyano, alkoxy, carbamoyl, sulfamoyl, monoalkylaminosulfonyl, or alkylsulfonyl, or alternatively two of R M , R N and R O are taken together to represent methylenedioxy),

(4) —OR P1 (wherein R P1 represents an alkyl optionally substituted by a group selected from the group consisting of hydroxy, dialkylamino, alkoxy, tetrahydrofuranyl, and cycloalkyl), or

(5) a heteroaryl optionally substituted by one or two groups selected from the group consisting of cyano, halogen, hydroxy, alkoxy, alkylcarbonyl, carbamoyl, alkyl, cycloalkyl, (cycloalkyl)alkyl, aralkyl, hydroxycarbonyl and alkoxyalkyl;

R 3 is H or hydroxy;

R 4 is H or alkyl; and

R 5 is H or alkyl.

4. A compound selected from the group consisting of the following (1) to (229):

(1)

(S)-4-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}piperazin-2-one,

(2)

N-{(S)-1-[2-{[(S)-1-(4-fluorophenyl)ethyl]amino}-6-(pyrazin-2-ylamino)pyrimidin-4-yl]pyrrolidin-3-yl}acetamide,

(3)

(S)-6-(3,3-difluoroazetidin-1-yl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(4)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(5)

(S)—N 2′ -[1-(4-fluorophenyl)ethyl]-N 6′ -(pyrazin-2-yl)-3,4′-bipyridine-2′,6′-diamine,

(6)

(S)—N 2′ -[1-(4-fluorophenyl)ethyl]-6-methoxy-N 6′ -(pyrazin-2-yl)-3,4′-bipyridine-2′,6′-diamine,

(7)

(S)-2′-[1-(4-fluorophenyl)ethylamino]-6′-(pyrazin-2-ylamino)-3,4′-bipyridin-6-ol,

(8)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(oxazol-5-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(9)

(S)-6-chloro-N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(10)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-[4-(methylsulfonyl)phenyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(11)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(1H-pyrazol-4-yl)pyrimidine-2,4-diamine,

(12)

(S)-2-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yloxy}ethanol,

(13) (S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(pyridin-3-yl)pyrimidine-2,4-diamine,

(14)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(pyridin-2-yl)pyrimidine-2,4-diamine,

(15)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(pyridin-4-yl)pyrimidine-2,4-diamine,

(16)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyrrolidin-2-one,

(17)

(S)-4-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}piperazin-2,6-dione,

(18)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}tetrahydropyrimidin-2(1H)-one,

(19)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(pyrrolidin-1-yl)pyrimidine-2,4-diamine,

(20)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-morpholino-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(21)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}imidazolidin-2-one,

(22)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-(oxazol-5-yl)-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(23)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-(6-methoxypyridin-3-yl)-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(24)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(1H-pyrazol-3-yl)pyrimidine-2,4-diamine,

(25)

(S)-4-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyridin-2-ol,

(26)

(S)-5-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyridin-2-ol,

(27)

N—((R)-1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyrrolidin-3-yl)acetamide,

(28)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)-4-(1H-pyrazol-4-yl)pyridine-2,6-diamine,

(29)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)-4-(1H-pyrazol-3-yl)pyridine-2,6-diamine,

(30)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-[3-(methylsulfonyl)phenyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(31)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-[4-(methylsulfonyl)phenyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(32)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(1-isopropyl-1H-pyrazol-4-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(33)

N-{(S)-1-[2-{[(S)-1-(4-fluorophenyl)ethyl]amino}-6-(pyrazin-2-ylamino)pyridin-4-yl]pyrrolidin-3-yl}acetamide,

(34)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-morpholino-N-6-(pyrazin-2-yl)pyridine-2,6-diamine,

(35)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)-4-thiomorpholinopyridine-2,6-diamine,

(36)

(S)-3-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}propan-1-ol,

(37)

(S)—N-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)acetamide,

(38)

(S)-6-(azetidin-1-yl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(39)

(S)-6-(3-fluoroazetidin-1-yl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(40)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-2-one,

(41)

(S)-4-(1-ethyl-1H-pyrazol-4-yl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(42)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-5-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(43)

(S)-4-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(44)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(thiazol-5-yl)pyrimidine-2,4-diamine,

(45)

1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyrrolidin-3-ol,

(46)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(5-methylthiazol-2-yl)-N 6 -(pyrazin-2-yl)pyrimidine-2,4,6-triamine,

(47)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)-4,5′-bipyrimidine-2,6-diamine,

(48)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-(2-methoxythiazol-5-yl)-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(49)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(thiazol-2-yl)pyrimidine-2,4-diamine,

(50)

(S)-5-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}picolinonitrile,

(51)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}piperidine-4-carboxamide,

(52)

(S)-5-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}picolinamide,

(53)

4-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}piperazine-2-carboxamide,

(54)

6-(3-aminopyrrolidin-1-yl)-N 2 -[(S)-1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(55)

N-(1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyrrolidin-3-yl)methanesulfonamide,

(56)

(S)-2-({2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}(2-hydroxyethyl)amino)ethan-1-ol,

(57)

(S)—N 4 -[2-(dimethylamino)ethyl]-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyrimidine-2,4,6-triamine,

(58)

1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}piperidine-3-carboxamide,

(59)

(S)-1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyrrolidine-2-carboxamide,

(60) (S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-[4-(methylsulfonyl)piperazin-1-yl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(61)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(1H-pyrrol-3-yl)pyrimidine-2,4-diamine,

(62)

(R)-1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-4-hydroxypyrrolidin-2-one,

(63)

N 2 -[(S)-1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-N 6 -[(tetrahydrofuran-2-yl)methyl]pyrimidine-2,4,6-triamine,

(64)

((S)-1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyrrolidin-2-yl)methanol,

(65)

((R)-1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyrrolidin-2-yl)methanol,

(66)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}piperidin-4-ol,

(67)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-ol,

(68)

1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}piperidin-3-ol,

(69)

(S)-5-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}nicotinonitrile,

(70)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(2H-tetrazol-5-yl)pyrimidine-2,4-diamine,

(71)

(S)—N 4 -(2-aminoethyl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyrimidine-2,4,6-triamine,

(72)

(S)—N-(2-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-ylamino}ethyl)methanesulfonamide,

(73)

(S)—N-(2-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-ylamino}ethyl)acetamide,

(74)

(S)-2-{2-[1-(4-fluorphenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-ylamino}acetamide,

(75)

(S)-4-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}benzamide

(76)

(S)-3-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}benzonitrile,

(77)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-(furan-3-yl)-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(78)

ethyl (S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}piperidin-4-carboxylate,

(79)

(S)-5-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}nicotinamide,

(80)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}piperidine-4-carboxylic acid,

(81)

(S)-2-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-ylamino}-2-phenylethanol,

(82)

(S)-2-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-ylamino}-3-phenylpropan-1-ol,

(83)

(R)-2-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-ylamino}-4-methylpentan-1-ol,

(84)

(S)-6-[2-(dimethylamino)ethoxy]-N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine

(85)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-1H-pyrazole-4-carboxylic acid,

(86)

(S)-3-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}benzamide,

(87)

(S)-6-(benzo[d] 1,3-dioxol-5-yl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(88)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-(2-fluoropyridin-4-yl)-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(89)

N 2 -[(S)-1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-[(tetrahydrofuran-2-yl)methoxy]pyrimidine-2,4-diamine,

(90)

(S)-2-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yloxy}ethanol,

(91)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-N 6 -[2-(pyrrolidin-1-yl)ethyl]pyrimidine-2,4,6-triamine,

(92)

(S)-3-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}isonicotinamide

(93)

(S)-3-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}isonicotinonitrile,

(94)

(S)-2-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-ylamino}-3-methylbutan-1-ol,

(95)

(S)—N 2 -[1-(4-chlorophenyl)ethyl]-6-[4-(methylsulfonyl)piperazin-1-yl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(96)

(1S,2S)-2-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yloxy}cyclohexanol,

(97)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -[(5-methylpyrazin-2-yl)methyl]-N 6 -(pyrazin-2-yl)pyrimidine-2,4,6-triamine,

(98)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(furan-2-ylmethyl)-N 6 -(pyrazin-2-yl)pyrimidine-2,4,6-triamine,

(99)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-N 6 -[1-(pyridin-3-yl)ethyl]pyrimidine-2,4,6-triamine,

(100)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-4-(hydroxymethyl)piperidin-4-ol,

(101)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-N 6 -(pyridin-2-ylmethyl)pyrimidine-2,4,6-triamine,

(102)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-N 6 -(pyridin-3-ylmethyl)pyrimidine-2,4,6-triamine,

(103)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-N 6 -(pyridin-4-ylmethyl)pyrimidine-2,4,6-triamine,

(104)

(S)-2-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-ylamino}-3-hydroxypropanamide,

(105)

(3S,4S)-1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}pyrrolidin-3,4-diol

(106)

N 2 -[(S)-1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)pyrimidine-2,4-diamine,

(107)

(S)-8-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-1,3-dioxo-8-azaspiro[4.5]decan-2-one,

(108)

(S)-4-(1-benzyl-1H-pyrazol-4-yl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(109)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-[4-(phenylsulfonyl)piperazin-1-yl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(110)

(S)-4-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}benzamide,

(111)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)-4-(1H-pyrrol-3-yl)pyridine-2,6-diamine,

(112)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(113)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-(4-methyl-1H-imidazol-1-yl)-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(114)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(4-methoxyphenyl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(115)

(S)-4-(4-fluorophenyl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine

(116)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-methyl-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(117)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-N-(methylsulfonyl)piperidine-4-carboxamide,

(118)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(furan-3-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(119)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-[4-(methylsulfonyl)piperazin-1-yl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(120)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}-4-(hydroxymethyl)piperidin-4-ol,

(121)

(S)-4-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}benzenesulfonamide,

(122)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-methoxy-N-6-(pyrazin-2-yl)pyridine-2,6-diamine,

(123)

4-{2-[(1S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}-1λ 6 ,4-thiomorpholin-1,1-dione,

(124)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}piperidin-4-ol,

(125)

(S)-1-(4-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}-1,4-diazepan-1-yl)ethanone,

(126)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)-N 4 -(pyrimidin-2-yl)pyridine-2,4,6-triamine,

(127)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)-N 4 -(pyridin-2-yl)pyridine-2,4,6-triamine,

(128)

N 2 -[(S)-1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)-4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)pyridine-2,6-diamine,

(129)

methyl (S)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinate,

(130)

(S)-4-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-N-methylbenzenesulfonamide,

(131)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(4-methyl-1H-imidazol-1-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(132)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 ,N 6 -di(pyrazin-2-yl)pyridine-2,4,6-triamine

(133)

(S)-4-(cyclopropylmethoxy)-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(134)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 2 -methyl-4-(1-methyl-1H-pyrazol-4-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine

(135)

(S)-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}methanol,

(136)

(S)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinic acid,

(137)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(2-methoxyethoxy)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(138)

(S)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidine-4-carbonitrile,

(139)

(S)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinonitrile,

(140)

(S)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(141)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-(1,2,4-oxadiazol-3-yl)-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(142)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(1,2,4-oxadiazol-3-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(143)

methyl (S)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)nicotinate,

(144)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N,N-dimethyl-6-(pyrazin-2-ylamino)isonicotinamide,

(145)

(S)—N-[2-(dimethylamino)ethyl]-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(146)

(S)—N-t-butyl-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(147)

(S)—N-ethyl-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(148)

(S)-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}[4-(methanesulfonyl)piperazin-1-yl]methanone,

(149)

(S)-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}(pyrrolidin-1-yl)methanone,

(150)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N-isopropyl-6-(pyrazin-2-ylamino)isonicotinamide,

(151)

(S)-1-{2-[(S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidine-2-carboxamide,

(152)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)-4-(tetrahydro-2H-pyran-4-yloxy)pyridine-2,6-diamine,

(153)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidine-3-carboxamide,

(154)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N-(2-hydroxyethyl)-6-(pyrazin-2-ylamino)isonicotinamide,

(155)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N-methyl-6-(pyrazin-2-ylamino)isonicotinamide,

(156)

(S)-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}(morpholino)methanone,

(157)

(S)—N-benzyl-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(158)

(S)—N-cyclopropyl-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(159)

(S)-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl} (4-methylpiperazin-1-yl)methanone,

(160)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N-(2-methoxyethyl)-6-(pyrazin-2-ylamino)isonicotinamide,

(161)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N-propyl-6-(pyrazin-2-ylamino)isonicotinamide,

(162)

(S)—N-cyclopropylmethyl-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(163)

(S)—N-cyclobutyl-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(164)

(S)—N-butyl-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(165)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N-isobutyl-6-(pyrazin-2-ylamino)isonicotinamide,

(166)

(S)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)-N-(2,2,2-trifluoroethyl)isonicotinamide,

(167)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N-(3-hydroxypropyl)-6-(pyrazin-2-ylamino)isonicotinamide,

(168)

(S)—N-(2-ethoxyethyl)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)isonicotinamide,

(169)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-N-methylazetidine-3-carboxamide,

(170)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(methoxymethyl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(171)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-N,N-dimethylazetidine-3-carboxamide,

(172)

(S)—N-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)methanesulfonamide,

(173)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-carbonitrile,

(174)

2-(4-fluorophenyl)-2-[4-(1-methyl-1H-pyrazol-4-yl)-6-(pyrazin-2-ylamino)pyridin-2-ylamino]ethanol,

(175)

(S)—N-ethyl-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidine-3-carboxamide,

(176)

(S)—N,N-diethyl-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidine-3-carboxamide,

(177)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}ethanone,

(178)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-(3-methoxyazetidin-1-yl)-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(179)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-3-methylazetidin-3-ol,

(180)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N-methyl-6-(pyrazin-2-ylamino)nicotinamide,

(181)

(S)-2-[1-(4-fluorophenyl)ethylamino]-N,N-dimethyl-6-(pyrazin-2-ylamino)nicotinamide,

(182)

(S)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)nicotinamide,

(183)

(S)-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-3-yl}(morpholino)methanone,

(184)

(S)—N-(cyclopropylmethyl)-2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)nicotinamide,

(185)

(S)—N-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl} azetidin-3-yl)ethanesulfonamide,

(186)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-N-isopropylazetidine-3-carboxamide,

(187)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-3-(trifluoromethyl)azetidin-3-ol,

(188)

(S)-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)(pyrrolidin-1-yl)methanone,

(189)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-N-(2-methoxyethyl)azetidine-3-carboxamide,

(190)

(S)-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)(piperidin-1-yl)methanone,

(191)

(S)-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)(morpholino)methanone,

(192)

(S)—N-(cyclopropyl)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidine-3-carboxamide,

(193)

(S)—N-(cyclopropylmethyl)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidine-3-carboxamide,

(194)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-N-(2-hydroxyethyl)azetidine-3-carboxamide,

(195)

(S)-3-cyclopropyl-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-ol,

(196)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-3-isopropylazetidin-3-ol,

(197)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}azetidin-3-ol,

(198)

(S)-3-cyclopropyl-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}azetidin-3-ol,

(199)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}-3-isopropylazetidin-3-ol,

(200)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}-3-methylazetidin-3-ol,

(201)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}-3-(trifluoromethyl)azetidin-3-ol,

(202)

(S)-4-(3,3-difluoroazetidin-1-yl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(203)

(S)—N-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}acetamide,

(204)

(S)—N-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}methanesulfonamide,

(205)

(S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}urea,

(206)

(S)-4-(3-cyclopropyl-3-methoxyazetidin-1-yl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(207)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(3-isopropyl-3-methoxyazetidin-1-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(208)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(3-methoxy-3-methylazetidin-1-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(209)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N 6 -(5-methylpyrazin-2-yl)pyridine-2,6-diamine,

(210)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-[1-(methanesulfonyl)piperidin-4-yl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(211)

(S)—N-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}propionamide,

(212) (S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(213)

(S)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-N 2 -[1-(4-fluorophenyl)ethyl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(214)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-[1-(methoxymethyl)-1H-pyrazol-4-yl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine,

(215)

(S)-6-[3-(dimethylamino)azetidin-1-yl]-N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(216)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-[3-(methylamino)azetidin-1-yl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(217)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)-6-[3-(pyrrolidin-1-yl)azetidin-1-yl]pyrimidine-2,4-diamine,

(218)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-(3-morpholinoazetidin-1-yl)-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(219)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-6-[3-(4-methylpiperazin-1-yl)azetidin-1-yl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(220)

(S)-(1-{1-[2-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)piperidin-4-ol,

(221)

4-{2-[(1S)-1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-1λ 6 ,4-thiomorpholin-1,1-dione,

(222)

(S)-1-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)urea,

(223)

(S)-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)methanol,

(224)

t-butyl (S)-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)methyl carbamate,

(225)

(S)-6-[3-(aminomethyl)azetidin-1-yl]-N 2 -[1-(4-fluorophenyl)ethyl]-N 4 -(pyrazin-2-yl)pyrimidine-2,4-diamine,

(226)

(S)—N-[(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)methyl]ethane sulfonamide,

(227)

(S)—N-[(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}azetidin-3-yl)methyl]acetamide,

(228)

(S)—N 2 -[1-(4-fluorophenyl)ethyl]-4-[3-morpholinoazetidin-1-yl]-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine, and

(229)

(S)-1-(1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}azetidin-3-yl)piperidin-4-ol;

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof described in claim 1 as an active ingredient.

6. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof described in claim 2 as an active ingredient.

7. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof described in claim 3 as an active ingredient.

8. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof described in claim 4 as an active ingredient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2011
From: FUJIHARA, HIDETAKA; ASAKI, TETSUO; HORI, KATSUTOSHI; NAITO, HARUNA
To: NIPPON SHINYAKU CO., LTD.
Reel/Frame 026672/0468 →
Priority Claims (2)
JP 2009-026470 · Feb 6, 2009 · national
JP 2009-276133 · Dec 4, 2009 · national
Continuity (1)
Related Publication 20110288065A1 · Nov 24, 2011